mwb research raises target for Drägerwerk stock to EUR 135.00

Published on 10/13/2026 at 09:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

FDA clearance ended a six-year US hurdle on October 9, 2026. Drägerwerk stock costs EUR 116.30 on October 13, 2026 versus EUR 115.80.

Key points in brief

mwb research raised its Drägerwerk price target from EUR 130.00 to EUR 135.00 after FDA clearance for the IACS VG8.1 system.
Drägerwerk reported second-quarter 2026 revenue of EUR 847.30 million, up 8.60 percent year over year, and earnings per share of EUR 1.58.
The stock was at EUR 116.30 at Lang & Schwarz on October 13, 2026, plus 0.43 percent versus the Xetra close of EUR 115.80 on October 12, 2026.
Third-quarter results are scheduled for October 29, 2026, followed by a Capital Markets Day on November 18, 2026.

Isometrische 3D-Darstellung der Medizintechnik-Wertschöpfungskette von Forschung bis Einsatz — Drägerwerk AG & Co. KGaA isometrische Wertschöpfungskette Forschung Produktion Krankenhaus Sicherheitsanwendung DE0005550636, Illustration mit AI erstellt.

mwb research raised its Drägerwerk price target from EUR 130.00 to EUR 135.00 and kept its Buy rating on October 9, 2026, according to Finanznachrichten.de reports. The trigger was FDA clearance for Dräger IACS VG8.1, which lifted a 2020 Warning Letter and removed remaining restrictions on the company's monitoring portfolio in the United States and other FDA-dependent markets.

What does the FDA clearance change?

The regulatory step is more important for medium-term sales than for immediate earnings. mwb research expects only limited short-term profit effects, while Dräger can rebuild US sales capacity, resume new-customer acquisition and combine its existing portfolio with monitoring solutions.

The same report lifted estimates for 2027 and 2028 and set the new target at EUR 135.00, up from EUR 130.00. That target is 16.10 percent above the Lang & Schwarz price of EUR 116.30, calculated in euros against the same reference price.

Three dated operating signals

On July 30, 2026, Drägerwerk reported second-quarter 2026 revenue of EUR 847.30 million, up 8.60 percent from EUR 779.99 million a year earlier, while earnings per share increased to EUR 1.58 from EUR 0.61, according to Finanzen.net. On September 29, 2026, Drägerwerk registered a 26-week high of EUR 125.40, as reported by Finanzen.net. The October 9 FDA development added a third dated signal and came with the EUR 135.00 target.

Margins remain the key test

Dräger's investor-relations guidance for fiscal year 2026 calls for currency-adjusted revenue growth of 2.00 percent to 6.00 percent and an EBIT margin of 5.00 percent to 7.50 percent, according to the Drägerwerk investor-relations page. The second-quarter EBIT margin was 5.40 percent, compared with 2.60 percent in the prior-year quarter, making execution against the full-year range the central operating test.

Next dates are already set

The next two dated events are third-quarter results on October 29, 2026, listed by MarketScreener, and a Capital Markets Day on November 18, 2026, identified in the mwb research report carried by Finanznachrichten.de.

Stock holds above the Xetra close

Drägerwerk stock was trading at EUR 116.30 at Lang & Schwarz on October 13, 2026 at 9:47 a.m. CEST, plus 0.43 percent versus the Xetra close of EUR 115.80 on October 12, 2026. The price remains EUR 9.10 below the 52-week high of EUR 125.40.

The further course of trading is shown by the continuously updated real-time quote of Drägerwerk stock.